Health outcomes associated with illicit prescription opioid injection: A systematic review

Journal of Addictive Diseases

Volumn 35, Issue 2, 2016, Pages 73-91

  Lake, Stephanie ^a   Kennedy, Mary Clare ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

injection drug use; opioid analgesics; people who inject drugs; Prescription opioids; systematic review

Indexed keywords

ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BUPRENORPHINE; DEXTROPROPOXYPHENE; DIAMORPHINE; DICYCLOVERINE; FENTANYL; METHADONE; METHAMPHETAMINE; MORPHINE; OPIATE; PARACETAMOL; PENTAZOCINE; PRESCRIPTION DRUG; STREET DRUG;

ARTICLE; DEPRESSION; DISEASE ASSOCIATION; DRUG MISUSE; DSM-IV; EXTERNAL VALIDITY; GENERAL HEALTH STATUS ASSESSMENT; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ICD-10; INTOXICATION; MEDICAL HISTORY; MENTAL HEALTH; OFF LABEL DRUG USE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SCAR FORMATION; SELF REPORT; SEROCONVERSION; SKIN ABSCESS; SKIN INFECTION; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; THROMBOSIS; VEIN OCCLUSION; COMPLICATION; HEALTH STATUS; SUBSTANCE ABUSE;

HEALTH STATUS; HUMANS; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84958054294     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2015.1127712     Document Type: Article

References (85)

1. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564-74.
2. World Drug Report 2014. Vienna: United Nations Office on Drugs and Crime, 2014.
3. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283 (13): 1710-14.
4. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008; 11 (2 Suppl): S63-88.
5. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010; 30 (2): 155-66.
6. Fischer B, Bibby M, Bouchard M. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction 2010; 105 (12): 2062-70.
7. Narcotic Drugs.: Estimated World Requirements for 2013. New York: United Nations International Narcotics Board, 2012.
8. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006; 81 (2): 103-7.
9. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011; 60 (43): 1487-92.
10. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012; 107 (7): 1318-27.
11. Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90 (1): 64-71.
12. Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend 2007; 87 (1): 98-102.
13. Roxburgh A, Ritter A, Grech K, Slade T, Burns L. Trends in drug use and related harms in Australia, 2001 to 2011. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2011.
14. Guichard A, Lert F, Calderon C, et al. Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 2003; 98 (11): 1585-97.
15. Larance B, Ambekar A, Azim T, et al. The availability, diversion, and injection of pharmaceutical opioids in South Asia. Drug Alcohol Rev 2011; 30 (3): 246-54.
16. Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction 2010; 105 (6): 991-1002.
17. Degenhardt L, Singleton J, Calabria B, et al. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend 2011; 113 (2-3): 88-95.
18. Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008; 27 (3): 253-62.
19. Darke S, Hall W, Weatherburn D, Lind B. Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug Alcohol Depend 1999; 54 (2): 155-61.
20. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin Inf Dis 2000; 30 (2): 374-9.
21. Roux P, Carrieri MP, Keijzer L, Dasgupta N. Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Drug Alcohol Rev 2011; 30 (3): 287-90.
22. Roy E, Arruda N, Bourgois P. The growing popularity of prescription opioid injection in downtown Montreal: new challenges for harm reduction. Subst Use Misuse 2011; 46 (9): 1142-50.
23. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011; 37 (4): 205-17.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med 2009; 151 (4): 264-9.
25. Okie S. A flood of opioids, a rising tide of deaths. New Engl J Med 2010; 363 (21): 1981-5.
26. International Statistical Classifications of Diseases and Related Health Outcomes 10th Revision.: World Health Organization; 2015. http://www.who.int/classifications/icd/icdonlineversions/en/ (accessed January 15, 2016
27. Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-84.
28. Barkin RL, Barkin SJ, Barkin DS. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. Am J Ther 2006; 13 (6): 534-42.
29. Xanodyne agrees to withdraw propxyphene from the U.S. market [Internet]. U.S. Food and Drug Administration; November 19, 2010 [cited March 17, 2015]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234350.htm (accessed March 17, 2015
30. Darvon painkiller pulled in Canada.: CBC News; 2010 [March 17, 2015]. http://www.cbc.ca/news/technology/darvon-painkiller-pulled-in-canada-1.969328 (accessed March 17, 2015
31. Hadland SE, DeBeck K, Kerr T, Feng C, Montaner JS, Wood E. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open 2014; 4 (7): e005419.
32. Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health 2013; 103 (1): e44-52.
33. Wylie JL, Shah L, Jolly AM. Demographic, risk behaviour, and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipe Canada., BMC Public Health 2006; 6 (229
34. Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and Hepatitis C virus among young injection drug users. Drugs (Abingdon Engl) 2015; 22 (1): 35-42.
35. Zibbell JE, Hart-Malloy R, Barry JL, Fan L, Flanigan C. Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health 2014; 104 (11): 2226-32.
36. Iversen J, Wand H, Gonnermann A, Maher L. Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. Int J Drug Policy 2010; 21 (6): 471-6.
37. Ojha S, Sigdel S, Meyer-Thompson H-G, Oechsler H, Verthein U. " South Asian cocktail"-The concurrent use of opioids, benzodiazepines, and antihistamines among injecting drug users in Nepal and associations with HIV risk behaviour. Harm Reduct J 2014; 11 (17). doi: 10.1186/1477-7517-11-17.
38. Aitken CK, Higgs PG, Hellard ME. Buprenorphine injection in Melbourne, Australia-An update. Drug Alcohol Rev 2008; 27 (2): 197-9.
39. Chelleng PK, Borkakoty BJ, Chetia M, Das HK, Mahanta J. Risk of hepatitis C infection among injection drug users in Mizoram, India. Indian J Med Res 2008; 128 (5): 640-6.
40. Das HK, Borkakoty BJ, Mahanta J, Medhi GK, Chelleng PK. Hepatitis C virus infection and risk behaviors among injection drug users of Nagaland. Indian J Gastroenterol 2007; 26 (5): 253-4.
41. Mahanta J, Borkakoty B, Das HK, Chelleng PK. The risk of HIV and HCV infections among injection drug users in northeast India. AIDS Care 2009; 21 (11): 1420-4.
42. Talu A, Rajaleid K, Abel-Ollo K, et al. HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: implications for intervention. Int J Drug Policy 2010; 21 (1): 56-63.
43. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti J-P. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96 (2): 267-72.
44. Carrieri M-P, Rey D, Loundou A, Lepeu G, Sobel A, Obadia Y. Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug Alcohol Depend 2003; 72 (1): 13-21.
45. Kerr T, Fairbairn N, Tyndall M, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend 2007; 87 (1): 39-45.
46. Pabayo R, Alcantara C, Kawachi I, Wood E, Kerr T. The role of depression and social support in non-fatal drug overdose among a cohort of injection drug users in a Canadian setting. Drug Alcohol Depend 2013; 132 (3): 603-9.
47. Havens JR, Oser CB, Knudsen HK, et al. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend 2011; 115 (1-2): 107-12.
48. Silva K, Schrager SM, Kecojevic A, Lankenau SE. Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs. Drug Alcohol Depend 2013; 128 (1-2): 104-10.
49. Fischer B, Brissette S, Brochu S, et al. Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. CMAJ 2004; 171 (3): 235-9.
50. Jenkins LM, Banta-Green CJ, Maynard C, et al. Risk factors for nonfatal overdose at Seattle-Area syringe exchanges. J Urban Health 2011; 88 (1): 118-28.
51. Degenhardt L, Black E, Breen C, et al. Trends in morphine prescriptions, illicit morphine use, and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006; 25 (5): 403-12.
52. Ambekar A, Rao R, Mishra AK, Agrawal A. Type of opioids injected: does it matter? A multicentric cross-sectional study of people who inject drugs. Drug Alcohol Rev 2015; 34 (1): 97-104.
53. Darke S, Topp L, Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the illicit drug reporting system. Drug Alcohol Rev 2002; 21 (1): 27-32.
54. Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction 2003; 98: 413-18.
55. Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend 1996; 43 (3): 191-8.
56. Marguery M-C, Chouini-Lalanne N, Drugeon C, et al. Hand edema and acrocyanosis: "puffy hand syndrome." Arch Dermatol 2006; 142: 1084-5.
57. Andresz V, Marcantoni N, Binder F, et al. Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis. Addiction 2006; 101 (9): 1347-51.
58. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005; 100 (2): 197-205.
59. Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008; 97 (1-2): 105-13.
60. Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis 2011; 30 (4): 334-41.
61. Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine, and amphetamine users. Addiction 1995; 90 (5): 607-14.
62. Havens JR, Oser CB, Leukefeld CG. Injection risk behaviors among rural drug users: implications for HIV prevention. AIDS Care 2011; 23 (5): 638-45.
63. Leclerc P, Roy E, Morissette C, Michel A, Parent R, SurvUDI Working Group. Extent and correlates of injection of prescription opioids for non-medical purposes in the SurvUDI network. 20th Annual Canadian Conference on HIV/AIDS Research, 2011; Toronto, Ontario: Can. J. Infect. Dis. Med. Microbiol
64. Firestone M, Fischer B. A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences, and drug availability. Harm Reduct J 2008; 5: 30.
65. Suryaprasad AG, White JZ, Xu FJ, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Inf Dis 2014; 59 (10): 1411-9.
66. Centers for Disease Control and Prevention (CDC). Community outbreak of HIV infection linked to injection drug use of oxymorphone-Indiana, 2015. Morb Mort Wkly Rep 2015; 64 (16): 443-4.
67. Lindenburg CEA, Krol A, Smit C, Buster MCA, Coutinho RA, Prins M. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS 2006; 20 (13): 1771-1775.
68. Mehta SH, Astemborski J, Kirk GD, et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis 2011; 203 (5): 587-94.
69. Hansen L, Penko J, Guzman D, Bangsberg DR, Miaskowski C, Kushel MB. Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals. J Pain Symptom Manage 2011; 42 (6): 893-902.
70. Newville H, Roley J, Sorensen JL. Prescription medication misuse among HIV-infected individuals taking antiretroviral therapy. J Subst Abuse Treat 2015; 48 (1): 56-61.
71. Anderson DT, Muto JJ. Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25 cases. J Anal Toxicol 2000; 24: 627-34.
72. Algren DA, Monteilh CP, Punja M, et al. Fentanyl-Associated fatalities among illicit drug users in Wayne County, Michigan (July 2005-May 2006). J Med Toxicol 2013; 9 (1): 106-15.
73. Kronstrand R, Druid H, Holmgren P, Rajs J. A cluster of fentanyl-related deaths among drug addicts in Sweden. Forensic Sci Int 1997; 88 (3): 185-95.
74. Kuhlman Jr JJ, McCaulley R, Valouch TJ, Behonick GS. Fentanyl use, misuse, and abuse: a summary of 23 post-mortem cases. J Anal Toxicol 2003; 27: 499-504.
75. Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10 (11): 1727-40.
76. Jones CG, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths United States, 2010. JAMA 2013; 309 (7): 657-59.
77. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006; 31 (6): 506-11.
78. Blanchon T, Boissonnas A, Vareseon I, Vidal-Trecan G. Homelessness and high-dosage buprenorphine misuse. Subst Use Misuse 2003; 38 (3-6): 429-42.
79. Kerr T, Small W, Hyshka E, Maher L, Shannon K. " It's more about the heroin:" injection drug users' response to an overdose warning campaign in a Canadian setting. Addiction 2013; 108 (7): 1270-6.
80. Partanen TA, Vikatmaa P, Tukiainen E, Lepantalo M, Vuola J. Outcome after injections of crushed tablets in intravenous drug abusers in the Helsinki University Central Hospital. Eur J Vasc Endovascular Surg 2009; 37 (6): 704-11.
81. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 2004; 150 (1): 1-10.
82. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse, and dependence on prescription opioids among U.S. adults: psychiatric, medical, and substance use correlates. Drug Alcohol Depend 2008; 94 (1-3): 38-47.
83. Sullivan LE, Edlund MJ, Zhang L, Unutzer J, Wells KB. Association between mental health disorders, problem drug user, and regular prescription opioid use. Arch Intern Med 2006; 166: 2087-93.
84. Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend 2008; 92 (1-3): 267-76.
85. Daniulaityte R, Falck RS, Wang J, Carlson RG. Illicit use of pharmaceutical opioids among young polydrug users in Ohio. Addict Behav 2009; 34 (8): 649-53.